FIELD: biotechnology.
SUBSTANCE: group of inventions including a polypeptide construct for providing a modified cell, a polynucleotide, an expression vector, a modified immune effector cell for use in adoptive cell therapy, a method for depleting a modified cell, and a method of the treatment of cancer is described. In one embodiment, the polypeptide construct contains truncated non-immunogenic HER1, CD20, CD52, and LNGFR polypeptides.
EFFECT: invention expands the arsenal of tools for use in adoptive cell therapy.
32 cl, 20 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSGENIC GENETIC LABELS AND METHODS OF USING | 2015 |
|
RU2729112C2 |
| TRANSGENIC GENETIC LABELS AND METHODS OF USE | 2015 |
|
RU2822461C1 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| DRUG-REGULATED TRANSGENIC EXPRESSION | 2015 |
|
RU2751920C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2752275C2 |
